Cargando…

Mapping the medical outcomes study HIV health survey (MOS-HIV) to the EuroQoL 5 Dimension (EQ-5D-3 L) utility index

BACKGROUND: Mapping of health-related quality-of-life measures to health utility values can facilitate cost-utility evaluation. Regression-based methods tend to lead to shrinkage of variance. This study aims to map the Medical Outcomes Study HIV Health Survey (MOS-HIV) to EuroQoL 5 Dimensions (EQ-5D...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Yuan, Thompson, Jennifer, Walker, A. Sarah, Paton, Nicholas I., Cheung, Yin Bun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6511158/
https://www.ncbi.nlm.nih.gov/pubmed/31077251
http://dx.doi.org/10.1186/s12955-019-1135-8
_version_ 1783417530503659520
author Shi, Yuan
Thompson, Jennifer
Walker, A. Sarah
Paton, Nicholas I.
Cheung, Yin Bun
author_facet Shi, Yuan
Thompson, Jennifer
Walker, A. Sarah
Paton, Nicholas I.
Cheung, Yin Bun
author_sort Shi, Yuan
collection PubMed
description BACKGROUND: Mapping of health-related quality-of-life measures to health utility values can facilitate cost-utility evaluation. Regression-based methods tend to lead to shrinkage of variance. This study aims to map the Medical Outcomes Study HIV Health Survey (MOS-HIV) to EuroQoL 5 Dimensions (EQ-5D-3 L) utility index, and to characterize the performance of three mapping methods, including ordinary least squares (OLS), equi-percentile method (EPM), and a recently proposed method called Mean Rank Method (MRM). METHODS: This is a secondary analysis of data from a randomized HIV treatment trial. Baseline data from 421 participants were used to develop mapping functions. Follow-up data from 236 participants was used to validate the mapping functions. RESULTS: In the training dataset, MRM and OLS, but not EPM, reproduced the observed mean utility (0.731). MRM, OLS and EPM under-estimated the standard deviation by 0.3, 26.6 and 1.7%, respectively. MRM had the lowest mean absolute error (0.143) and highest intraclass correlation coefficient (0.723) with the observed utility values, whereas OLS had the lowest mean squared error (0.038) and highest R-squared (0.542). Regressing the MRM- and OLS-mapped utility values upon body mass index and log-viral load gave covariate associations comparable to those estimated from the observed utility data (all P > 0.10). EPM did not achieve this property. Findings from the validation data were similar. CONCLUSIONS: Functions are available for mapping the MOS-HIV to the EQ-5D-3 L utility values. MRM and OLS were comparable in terms of agreement with the observed utility values at the individual level. MRM had better performance at the group level in terms of describing the utility distribution. TRIAL REGISTRATION: NCT00988039. Registered 30 September 2009. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12955-019-1135-8) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6511158
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-65111582019-05-20 Mapping the medical outcomes study HIV health survey (MOS-HIV) to the EuroQoL 5 Dimension (EQ-5D-3 L) utility index Shi, Yuan Thompson, Jennifer Walker, A. Sarah Paton, Nicholas I. Cheung, Yin Bun Health Qual Life Outcomes Research BACKGROUND: Mapping of health-related quality-of-life measures to health utility values can facilitate cost-utility evaluation. Regression-based methods tend to lead to shrinkage of variance. This study aims to map the Medical Outcomes Study HIV Health Survey (MOS-HIV) to EuroQoL 5 Dimensions (EQ-5D-3 L) utility index, and to characterize the performance of three mapping methods, including ordinary least squares (OLS), equi-percentile method (EPM), and a recently proposed method called Mean Rank Method (MRM). METHODS: This is a secondary analysis of data from a randomized HIV treatment trial. Baseline data from 421 participants were used to develop mapping functions. Follow-up data from 236 participants was used to validate the mapping functions. RESULTS: In the training dataset, MRM and OLS, but not EPM, reproduced the observed mean utility (0.731). MRM, OLS and EPM under-estimated the standard deviation by 0.3, 26.6 and 1.7%, respectively. MRM had the lowest mean absolute error (0.143) and highest intraclass correlation coefficient (0.723) with the observed utility values, whereas OLS had the lowest mean squared error (0.038) and highest R-squared (0.542). Regressing the MRM- and OLS-mapped utility values upon body mass index and log-viral load gave covariate associations comparable to those estimated from the observed utility data (all P > 0.10). EPM did not achieve this property. Findings from the validation data were similar. CONCLUSIONS: Functions are available for mapping the MOS-HIV to the EQ-5D-3 L utility values. MRM and OLS were comparable in terms of agreement with the observed utility values at the individual level. MRM had better performance at the group level in terms of describing the utility distribution. TRIAL REGISTRATION: NCT00988039. Registered 30 September 2009. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12955-019-1135-8) contains supplementary material, which is available to authorized users. BioMed Central 2019-05-10 /pmc/articles/PMC6511158/ /pubmed/31077251 http://dx.doi.org/10.1186/s12955-019-1135-8 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Shi, Yuan
Thompson, Jennifer
Walker, A. Sarah
Paton, Nicholas I.
Cheung, Yin Bun
Mapping the medical outcomes study HIV health survey (MOS-HIV) to the EuroQoL 5 Dimension (EQ-5D-3 L) utility index
title Mapping the medical outcomes study HIV health survey (MOS-HIV) to the EuroQoL 5 Dimension (EQ-5D-3 L) utility index
title_full Mapping the medical outcomes study HIV health survey (MOS-HIV) to the EuroQoL 5 Dimension (EQ-5D-3 L) utility index
title_fullStr Mapping the medical outcomes study HIV health survey (MOS-HIV) to the EuroQoL 5 Dimension (EQ-5D-3 L) utility index
title_full_unstemmed Mapping the medical outcomes study HIV health survey (MOS-HIV) to the EuroQoL 5 Dimension (EQ-5D-3 L) utility index
title_short Mapping the medical outcomes study HIV health survey (MOS-HIV) to the EuroQoL 5 Dimension (EQ-5D-3 L) utility index
title_sort mapping the medical outcomes study hiv health survey (mos-hiv) to the euroqol 5 dimension (eq-5d-3 l) utility index
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6511158/
https://www.ncbi.nlm.nih.gov/pubmed/31077251
http://dx.doi.org/10.1186/s12955-019-1135-8
work_keys_str_mv AT shiyuan mappingthemedicaloutcomesstudyhivhealthsurveymoshivtotheeuroqol5dimensioneq5d3lutilityindex
AT thompsonjennifer mappingthemedicaloutcomesstudyhivhealthsurveymoshivtotheeuroqol5dimensioneq5d3lutilityindex
AT walkerasarah mappingthemedicaloutcomesstudyhivhealthsurveymoshivtotheeuroqol5dimensioneq5d3lutilityindex
AT patonnicholasi mappingthemedicaloutcomesstudyhivhealthsurveymoshivtotheeuroqol5dimensioneq5d3lutilityindex
AT cheungyinbun mappingthemedicaloutcomesstudyhivhealthsurveymoshivtotheeuroqol5dimensioneq5d3lutilityindex
AT mappingthemedicaloutcomesstudyhivhealthsurveymoshivtotheeuroqol5dimensioneq5d3lutilityindex